全文获取类型
收费全文 | 131458篇 |
免费 | 7528篇 |
国内免费 | 731篇 |
专业分类
耳鼻咽喉 | 1220篇 |
儿科学 | 4146篇 |
妇产科学 | 3030篇 |
基础医学 | 18641篇 |
口腔科学 | 4563篇 |
临床医学 | 11707篇 |
内科学 | 29836篇 |
皮肤病学 | 3164篇 |
神经病学 | 12811篇 |
特种医学 | 3221篇 |
外国民族医学 | 3篇 |
外科学 | 12209篇 |
综合类 | 667篇 |
一般理论 | 57篇 |
预防医学 | 13287篇 |
眼科学 | 2248篇 |
药学 | 9272篇 |
中国医学 | 547篇 |
肿瘤学 | 9088篇 |
出版年
2024年 | 139篇 |
2023年 | 1175篇 |
2022年 | 2488篇 |
2021年 | 4231篇 |
2020年 | 2631篇 |
2019年 | 3642篇 |
2018年 | 4301篇 |
2017年 | 3189篇 |
2016年 | 3662篇 |
2015年 | 4081篇 |
2014年 | 5341篇 |
2013年 | 7006篇 |
2012年 | 10623篇 |
2011年 | 11144篇 |
2010年 | 6058篇 |
2009年 | 5131篇 |
2008年 | 8912篇 |
2007年 | 9065篇 |
2006年 | 8309篇 |
2005年 | 7772篇 |
2004年 | 7014篇 |
2003年 | 6414篇 |
2002年 | 5775篇 |
2001年 | 1039篇 |
2000年 | 918篇 |
1999年 | 1013篇 |
1998年 | 999篇 |
1997年 | 787篇 |
1996年 | 679篇 |
1995年 | 566篇 |
1994年 | 548篇 |
1993年 | 460篇 |
1992年 | 497篇 |
1991年 | 350篇 |
1990年 | 330篇 |
1989年 | 334篇 |
1988年 | 282篇 |
1987年 | 240篇 |
1986年 | 271篇 |
1985年 | 199篇 |
1984年 | 203篇 |
1983年 | 176篇 |
1982年 | 202篇 |
1981年 | 175篇 |
1980年 | 163篇 |
1979年 | 128篇 |
1978年 | 124篇 |
1977年 | 107篇 |
1976年 | 98篇 |
1974年 | 91篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
83.
Margaret MacDonald Matthew Law John Kaldor Jim Hales Gregory J. Dore 《The International journal on drug policy》2003,14(5-6):353
Objective: To examine the effectiveness of needle and syringe programmes (NSPs) in preventing HIV transmission among injecting drug users (IDUs).Methods: An ecological study design was used to determine change in HIV prevalence among injecting drug users between cities with and without NSPs. Several data sources, such as electronic journal databases, surveillance reports, websites, and index review of relevant journals, were used to identify studies of HIV seroprevalence among IDUs, and presence of NSPs. The rate of change in HIV prevalence was estimated by regression analysis.Results: There were 778 years of data from 99 cities globally included in the analysis. HIV prevalence decreased by 18.6% per annum in cities that introduce NSPs, and increased by 8.1% in cities that had never introduced NSPs (mean difference −24.7% [95% CI: −43.8, 0.5%], P=0.06). The mean difference was –33% when comparison was weighted to one over the variance of the regression estimator (29% decrease in cities with NSPs and 5% increase in cities without NSPs, P<0.001). When analysis was restricted to cities with first HIV seroprevalence less than 10%, the average annual change in seroprevalence was 18% lower in cities with NSPs (P=0.03).Conclusions: Despite the inherent limitations within an ecological study design, the study provides additional evidence that NSPs reduce transmission of HIV infection. The rapid spread of HIV among IDU populations and increasing rates of injecting in many countries calls for scaling up of NSPs as well as other harm reduction strategies. 相似文献
84.
85.
Maria de Fátima Haueisen S. Diniz Valéria M. Azeredo Passos Marco Túlio C. Diniz 《Nutrition (Burbank, Los Angeles County, Calif.)》2010,26(10):925-931
ObjectiveThis review analyzes the literature concerning gut peptides and bariatric surgery, from 2005 to July 2009. In particular, we are interested in whether, and how, gastrointestinal peptide alterations following surgery interfere with appetite/satiety, and what role they might play in the resolution of comorbidities.Research methods and procedurePubMed/MEDLINE and ISI Web of Knowledge were used to search for human studies concerning gut peptides profiles after any bariatric operation technique.ResultsMost of the studies reviewed had longitudinal design, short follow-up, and low statistical power. The diversity of study results may be partially explained by methodological aspects. Glucagon-like peptide-1, gastric inhibitory peptide, and peptide YY alterations may contribute to the excellent results in glycemic control of diabetics. Results do vary depending on bariatric operation technique; this is particularly evident in the case of ghrelin, which has been much studied in recent years. Ghrelin suppression has been linked to increased satiety, alterations in energy homeostasis, and better glucose metabolism.ConclusionsThere is a lack of long-term data on gastrointestinal hormone profiles after bariatric surgery and the studies have many methodological pitfalls. We still need prospective, long-term, good methodological studies in this area. 相似文献
86.
87.
Laura Cisneros Maria-Carlota Londo?o Carmen Blasco Ramón Bataller Rosa Miquel Miquel Bruguera Pere Ginès Antoni Rimola 《Liver transplantation》2007,13(7):1017-1027
The pathogenic mechanisms of accelerated graft fibrosis in hepatitis C recurrence after liver transplantation (LT) are not well established. The aim of the study was to assess whether a greater activation of hepatic stellate cells (HSC), the major collagen-producing cells in the liver, can occur in these patients as compared to non-LT patients with chronic hepatitis C. We determined the amount of activated HSC by computer-based morphometric analysis of alpha-smooth muscle actin (alphaSMA)-positive cells and the hepatic TGFbeta(1) expression by immunohistochemistry in 46 LT patients with hepatitis C recurrence, 35 non-LT patients with chronic hepatitis C, and 16 controls. Hepatic alphaSMA and TGFbeta(1) expression was higher in LT patients with hepatitis C recurrence than in controls and was correlated with fibrosis stage and progression rate. No significant difference in alphaSMA and TGFbeta(1) expression was observed between LT and non-LT patients with hepatitis C, with the exception of a higher transforming growth factor beta-1 (TGFbeta(1)) expression in non-LT patients in the early stages of fibrosis. LT patients receiving cyclosporine (CsA) or tacrolimus (FK) had a similar fibrosis progression rate and alphaSMA and TGFbeta(1) expression. In conclusion, the accelerated fibrosis observed in LT patients with hepatitis C recurrence does not seem to be related to a greater amount of activated HSC and TGFbeta(1) expression in the grafts of these patients as compared to non-LT patients with chronic hepatitis C. In LT patients, the amount of activated HSC and TGFbeta(1) expression correlated with fibrosis stage and progression, without any apparent influence of the type of calcineurin inhibitor administered. 相似文献
88.
ContextZD4054 is a specific endothelin A (ETA) receptor antagonist being investigated for the treatment of hormone-resistant prostate cancer (HRPC). ZD4054 binds specifically to the ETA receptor, with no detectable activity at the ETB receptor. In preclinical studies, ZD4054 inhibited endothelin (ET-1)-mediated changes in cellular invasiveness in vitro, and inhibited angiogenesis and growth of tumour xenografts in vivo. Consistent with its specific binding profile, ZD4054 inhibited ETA-receptor-mediated antiapoptotic events while allowing ETB-receptor-mediated proapoptotic signalling.Evidence acquisitionThe preclinical and clinical activity of ZD4054 is reviewed.Evidence synthesisIn the clinical setting, stable levels of circulating ET-1 following single ZD4054 doses up to 240 mg demonstrated the absence of ZD4054 activity at the ETB receptor. ZD4054 is cleared principally via the urine, with a terminal elimination half-life of approximately 8–12 hours and with little accumulation after once-daily oral dosing.In a Phase 2 trial, patients with metastatic HRPC who were pain free or mildly symptomatic for pain were randomized to once-daily oral tablets of ZD4054 10 mg (n = 107), or 15 mg (n = 98), or matched placebo (n = 107). ZD4054 was generally well tolerated in this population, with an adverse effect profile consistent with its known pharmacological activity. The most common adverse effects were headache, peripheral oedema and nasal congestion. At the primary analysis there was no statistically significant difference in time to progression between the ZD4054-treated groups and placebo (hazard ratio [HR]: ZD4054 10 mg, 0.88 [80% CI 0.71, 1.09]; ZD4054 15 mg, 0.83 [0.66, 1.03]). However, a promising signal for prolonged overall survival was observed, which was sustained at a subsequent analysis (HR versus placebo: ZD4054 10 mg, 0.55 [80% CI 0.41, 0.73]; ZD4054 15 mg, 0.65 [0.49, 0.86]).ConclusionsThese results support the strategy of targeting the ETA receptor in prostate cancer, and mandate further investigation of ZD4054 in Phase 3 clinical trials. 相似文献
89.
90.
Giorgio Ciprandi Mara De Amici Simone Negrini Gianluigi Marseglia Maria Angela Tosca 《International immunopharmacology》2009,9(10):1247-1249
Two new T cell subsets may be involved in allergic rhinitis (AR) pathogenesis: Th17 and T regulatory cells, mainly producing IL-17 and TGF-β respectively. Successful Sublingual Immunotherapy (SLIT) induces relevant immunological changes, thus the aim of this study was to evaluate serum IL-17 and TGF-β levels in AR patients treated with SLIT for 2 years. Patients' blood samples were collected before initiating SLIT (baseline), three months after the end of the first pre-seasonal SLIT course, and at the end of the second pre-seasonal course. IL-17 was detectable only in the most severe allergic patients. SLIT significantly induced an increase in serum TGF-β levels. There was moreover a significant relationship between TGF-β and symptom severity and drug use at the end of the study. Therefore, this study provides clinically relevant evidence that two pre-seasonal SLIT courses may significantly affect serum TGF-β levels. 相似文献